Skip to main navigation Skip to search Skip to main content

Assessment of Cardiac Frailty in Preclinical Models of Heart Failure and Ageing – Parallels Between Discovery and the Clinic

  • Abhipree Sharma
  • , Julee McDonagh
  • , Doan T.M. Ngo
  • , Miles J. De Blasio
  • , Caleb Ferguson
  • , Rebecca H. Ritchie
  • Monash University
  • The University of Sydney
  • University of Wollongong
  • Blacktown Hospital
  • University of Newcastle
  • University of Melbourne
  • Centre for Chronic & Complex Care Research

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Frailty is a state of reduced physiological reserve and has been identified as a prognostic indicator in older people with cardiovascular disease and heart failure (HF). Frailty contributes to increased vulnerability and worse outcomes, leading to increased morbidity and mortality. Clinical screening for frailty is increasingly recognised as an essential factor for risk stratification in HF and geriatric care, however its adoption in preclinical research and its uptake into clinical practice remains limited. In clinical practice, biomarkers are often not incorporated into routine frailty assessment. Nevertheless, several emerging biomarkers—reflecting inflammation, metabolic dysregulation, sarcopenia, and cardiovascular stress—are increasingly recognised as valuable adjuncts to established frailty assessment tools. Given that facilitating healthy ageing requires enhancing strategies to delay, slow, or reverse cardiac frailty, this discussion paper examines the current landscape of frailty assessment across the translational spectrum, advocating for an integration of frailty measures and biomarkers into preclinical discovery across the domains of physical/cognitive, systemic and cardiac phenotype. We call on cardiac preclinical discovery researchers to include or assess measures of frailty across these domains in their animal models of cardiomyopathy (heart failure with reduced ejection fraction [HFrEF], myocardial infarction [MI], heart failure with preserved ejection fraction [HFpEF], diabetes, cardiovascular-kidney metabolic disease), as well as prioritising sex-inclusive cohorts and inclusion of older animals, hence enhancing translational relevance and aligning discovery science with clinical priorities. Requiring the incorporation of these frailty measures by funding agencies and journals, alongside current measures of altered cardiac phenotype and function, into preclinical discovery, will be critical for identifying novel drivers of frailty and developing interventions that improve both lifespan and functional health in an ageing population with HF.

Original languageEnglish
Pages (from-to)728-744
Number of pages17
JournalHeart Lung and Circulation
Volume35
Issue number6
DOIs
Publication statusPublished - Jun 2026
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2026 The Author(s)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Animal-models
  • Disease modelling
  • Frailty assessment
  • Frailty screening
  • Heart failure
  • Preclinical research

Fingerprint

Dive into the research topics of 'Assessment of Cardiac Frailty in Preclinical Models of Heart Failure and Ageing – Parallels Between Discovery and the Clinic'. Together they form a unique fingerprint.

Cite this